Commentary
==========

The annual incidence of hospitalization for acute UGIB is 1 in 1,000 people in North America, translating to 300,000 admissions yearly \[[@B1]\] and a total annual expenditure of \$2.5 billion \[[@B2]\]. The mortality from UGIB is approximately 10% and may reach 35% in patients hospitalized with another medical condition \[[@B3]\].

In the critically ill, a more restrictive strategy has been used for blood transfusion on the basis of a growing body of data indicating worse outcomes with red blood cell transfusions in this population \[[@B4],[@B5]\]. However, the threshold for blood transfusion in patients with UGIB has been controversial since hemoglobin values may underestimate the blood loss. Over the past decade, consensus guidelines suggested using a more conservative approach based on experimental studies, trials in other populations, and physiologic data \[[@B6],[@B7]\]. A prospective observational study in patients with UGIB showed that blood transfusion in the first 12 hours in patients presenting with hemoglobin of more than 8 g/dL increased mortality and rebleeding rates in comparison with patients not receiving blood transfusion in the first 12 hours \[[@B8]\]. A recent Cochrane meta-analysis of randomized controlled trials examining red blood cell transfusion for the management of UGIB found only three trials and showed higher mortality and rebleeding rates for a liberal transfusion strategy. However, these studies had design flaws and were underpowered \[[@B9]\].

The Transfusion Strategies for Acute Upper Gastrointestinal Bleeding trial \[[@B10]\] is a randomized controlled trial testing liberal and conservative strategies for patients with UGIB. The authors hypothesized that a restrictive threshold for red blood cell transfusion (transfusion when hemoglobin was below 7 g/dL with a goal of 7 to 9 g/dL) was safer and more effective than a liberal transfusion strategy (transfusion when hemoglobin was below 9 g/dL with a goal of 9 to 11 g/dL). Patients with low mortality and low risk of rebleeding were excluded by using the Rockall score, which is based on age, presence or absence of shock, comorbidities, reason for bleeding, and major stigmata of recent hemorrhage \[[@B11]\]. The primary end-point was all-cause mortality rate at 45 days. Secondary outcomes were rebleeding rate and adverse events. The random assignment was stratified by the presence or absence of cirrhosis. Twenty-eight percent in the restrictive group and 31% in the liberal group were in shock upon enrollment. The restrictive-strategy group had a lower mortality rate than the liberal group (5% versus 9%, *P* = 0.02) at 45 days, and the relative-risk reduction was 45% and the number needed to treat was 25 patients for the restrictive strategy intervention. In addition, the liberal-strategy group had higher frequency of rebleeding, interventions (transjugular intrahepatic portosystemic shunt for variceal bleeding and surgery in non-variceal bleeding), and cardiac and pulmonary adverse effects.

The study had several strengths. First, it used a randomized controlled design and a patient-centered outcome with an adequate number of patients. The protocol was well devised for hemoglobin checks and management of complications. The study also had a few concerns. The protocol allowed the physicians to transfuse in the presence of signs and symptoms of anemia in case of a massive bleed and if a surgical intervention was planned. However, protocol violations in transfusing blood occurred in both arms, and more violations occurred in the restrictive group (9% versus 3%).

Multiple mechanisms have been suggested by previous animal and physiologic studies to explain the increased mortality and morbidity with a liberal transfusion strategy \[[@B12]-[@B14]\]. These include clot rupture, coagulopathy, changes in stored red blood cells (the storage lesion), and immunomodulation. The duration of storage of red blood cells was similar in the two groups, and the coagulation laboratory test results were also similar in the two groups \[[@B15]\], suggesting that these pathways may not solely explain differences in outcomes.

Although this study was conducted only in patients with UGIB, a similar restrictive approach should be considered by physicians caring for critically ill patients presenting with other acute bleeding episodes, such as lower GI bleeding and retroperitoneal bleeding. However, physicians should be careful about extrapolating these results to patients with massive bleeding or those with bleeding and acute coronary syndrome.

Recommendation
==============

A restrictive strategy for blood transfusions should be used for UGIB. The results of this study reinforce the growing notion that ?less is more? for a blood transfusion strategy in the critically ill.
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CI: Confidence interval; GI: Gastrointestinal bleeding; HR: Hazard ratio; UGIB: Upper gastrointestinal bleeding.
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